[Low-molecular-weight heparin in the prevention of thromboembolism in pregnant thrombophilic patients].
Prophylaxis of thromboembolism with low molecular weight heparin (LMWH) may offer some advantages over unfractionated heparin during pregnancy. Controlled studies with LMWH for thromboprophylaxis in pregnancy are failing, although according to some recent studies LMWH did not cross the placental barrier. LMWH as thromboprophylactic agent was used in three young pregnant women with familial thrombophilia (two with PC one with AT-III deficiency). According to the bodyweight of patients the applied doses of LMWH were 5,000-10,000 ICU once daily. Laboratory control (determination of anti-FXa activity in plasma samples) was made monthly. The three pregnancies were uneventful, thromboembolic or haemorrhagic complications did not develop. Newborns were healthy, with no coincide of disturbances of haemostasis. The LMWH-demand is certainly increased at the late period of pregnancy. LMWH as thromboprophylaxis is recommended for pregnants with familial thrombophilia. The necessary dose of Fraxiparine may be 70 ICU/kg/day in the first and 100 ICU/kg/day in the second half of pregnancy.
Boda
Z
Z
Debreceni Orvostudományi Egyetem II.
László
P
P
Rejtö
L
L
Tornai
I
I
Pfliegler
G
G
Rák
K
K
D000328:Adult; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007866:Leg / Q000098:blood supply; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000517:prevention & control; D013923:Thromboembolism / Q000188:drug therapy / Q000235:genetics* / Q000517:prevention & control
D006495:Heparin, Low-Molecular-Weight
Thromboembolia prophylaxis kis molekulatömegü heparin alkalmazásával thrombophiliás terhesekben.